Cargando…

Cost–consequence analysis of (18)F-fluciclovine for the staging of recurrent prostate cancer

Background: Current detection methodologies are often unable to identify the location and extent of recurrent prostate cancer (PCa) leading potentially to ‘futile’ local therapies in the presence of metastatic disease. The use of (18) F-fluciclovine PET/CT may lead to better patient management. Obje...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Ivar S, Hathway, Joanne, Cyr, Philip, Gauden, David, Gardiner, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170335/ https://www.ncbi.nlm.nih.gov/pubmed/32341772 http://dx.doi.org/10.1080/20016689.2020.1749362

Ejemplares similares

Detection of Recurrent Prostate Cancer With (18)F-Fluciclovine PET/MRI
por: Selnæs, Kirsten Margrete, et al.
Publicado: (2020)

(18)F-Fluciclovine ((18)F-FACBC) PET imaging of recurrent brain tumors
por: Michaud, Laure, et al.
Publicado: (2019)

Initial Institutional Experience with 18F-Fluciclovine PET-CT in Biochemical Recurrence of Prostate Cancer
por: Farkas, Amy B., et al.
Publicado: (2021)

(18)F-Fluciclovine PET/CT performance in biochemical recurrence of prostate cancer: a systematic review
por: Rais-Bahrami, Soroush, et al.
Publicado: (2021)

[(18)F]Fluciclovine PET/CT Improves the Clinical Management of Early Recurrence Prostate Cancer Patients
por: Nappi, Anna Giulia, et al.
Publicado: (2022)

Texture Analysis of F-18 Fluciclovine PET/CT to Predict Biochemically Recurrent Prostate Cancer: Initial Results
por: Kang, Hakmook, et al.
Publicado: (2020)

The Diagnostic Role of (18)F-Choline, (18)F-Fluciclovine and (18)F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis
por: Wang, Rang, et al.
Publicado: (2021)

Impact of (18)F-fluciclovine PET/CT on salvage radiotherapy plans for men with recurrence of prostate cancer postradical prostatectomy
por: Payne, Heather, et al.
Publicado: (2021)

F-18 Fluciclovine PET-CT Findings and Pseudoprogression on Immunotherapy
por: Poindexter, Bradley C, et al.
Publicado: (2022)

[(18)F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis
por: Parent, Ephraim E., et al.
Publicado: (2020)

Prediction of prostate cancer aggressiveness using (18)F-Fluciclovine (FACBC) PET and multisequence multiparametric MRI
por: Movahedi, Parisa, et al.
Publicado: (2020)

Understanding and Improving (18)F-Fluciclovine PET/CT Reports: A Guide for Physicians Treating Patients with Biochemical Recurrence of Prostate Cancer
por: Lowentritt, Benjamin H., et al.
Publicado: (2020)

(18)F-Fluciclovine–Avid Axillary Lymph Nodes After COVID-19 Vaccination on PET/CT for Suspected Recurrence of Prostate Cancer
por: Peacock, Justin G., et al.
Publicado: (2022)

Simultaneous (18)F-fluciclovine Positron Emission Tomography and Magnetic Resonance Spectroscopic Imaging of Prostate Cancer
por: Esmaeili, Morteza, et al.
Publicado: (2018)

Bayesian penalised likelihood reconstruction (Q.Clear) of (18)F-fluciclovine PET for imaging of recurrent prostate cancer: semi-quantitative and clinical evaluation
por: Teoh, Eugene J, et al.
Publicado: (2018)

18F-Fluciclovine Positron Emission Tomography in Prostate Cancer: A Systematic Review and Diagnostic Meta-Analysis
por: Biscontini, Giuseppina, et al.
Publicado: (2021)

Effect of Androgen Deprivation Therapy on the Results of PET/CT with 18F-Fluciclovine in Patients with Metastatic Prostate Cancer
por: Bach-Gansmo, Tore, et al.
Publicado: (2022)

[(18)F]Fluciclovine PET discrimination between high- and low-grade gliomas
por: Parent, Ephraim E., et al.
Publicado: (2018)

Imaging Glioblastoma With (18)F-Fluciclovine Amino Acid Positron Emission Tomography
por: Scarpelli, Matthew L., et al.
Publicado: (2022)

[(18)F]fluciclovine vs. [(18)F]fluorocholine Positron Emission Tomography/Computed Tomography: A Head-to-Head Comparison for Early Detection of Biochemical Recurrence in Prostate Cancer Patients
por: Ferrari, Cristina, et al.
Publicado: (2022)

Comparison of [(18)F]fluciclovine and [(18)F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
por: Stokke, Caroline, et al.
Publicado: (2022)

Assessment of Amino Acid/Drug Transporters for Renal Transport of [(18)F]Fluciclovine (anti-[(18)F]FACBC) in Vitro
por: Ono, Masahiro, et al.
Publicado: (2016)

18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy
por: Malviya, Gaurav, et al.
Publicado: (2020)

18F-Fluciclovine Uptake in an Incidentally Discovered Meningioma in a Patient With a History of Metastatic Prostate Cancer: A Case Report
por: Touma, Danielle A, et al.
Publicado: (2023)

Fluciclovine positron emission tomography in the setting of biochemical recurrence following local therapy of prostate cancer
por: Glaser, Zachary A., et al.
Publicado: (2018)

Characterising (18)F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging
por: Scott, N. P., et al.
Publicado: (2021)

Exploratory Analysis of Serial (18)F-fluciclovine PET-CT and Multiparametric MRI during Chemoradiation for Glioblastoma
por: Fatania, Kavi, et al.
Publicado: (2022)

Glioblastoma PET/MRI: kinetic investigation of [(18)F]rhPSMA-7.3, [(18)F]FET and [(18)F]fluciclovine in an orthotopic mouse model of cancer
por: Lindemann, Marcel, et al.
Publicado: (2022)

BIMG-12. [18F]FLUCICLOVINE PET TO DISTINGUISH PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN POST-TREATMENT GLIOBLASTOMA
por: Nabavizadeh, Ali, et al.
Publicado: (2021)

(18)F-Fluciclovine PET to distinguish treatment-related effects from disease progression in recurrent glioblastoma: PET fusion with MRI guides neurosurgical sampling
por: Henderson, Fraser, et al.
Publicado: (2020)

The utility of [(18)F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate-Resistant Prostate Cancer Patients (nmCRPCp): diagnostic performance and impact on management
por: Soliman, Moataz, et al.
Publicado: (2023)

The Role of [(18)F]Fluciclovine PET/CT in the Characterization of High-Risk Primary Prostate Cancer: Comparison with [(11)C]Choline PET/CT and Histopathological Analysis
por: Zanoni, Lucia, et al.
Publicado: (2021)

Comparison of time curves from dynamic (18)F-fluciclovine positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging for primary prostate carcinomas
por: Tulipan, Andreas Julius, et al.
Publicado: (2018)

NEIM-02 CHARACTERIZATION OF LARGE BRAIN METASTASES WITH(18)F-FLUCICLOVINE PET/CT TREATED WITH STAGED STEREOTACTIC RADIOSURGERY (SSRS): INTERIM ANALYSIS OF A PILOT STUDY
por: Rosa, Alonso La, et al.
Publicado: (2023)

NEIM-03 A MULTICENTER PHASE 3 TRIAL IN PROGRESS: DIAGNOSTIC PERFORMANCE OF(18)F-FLUCICLOVINE PET FOR THE DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY (REVELATE)
por: Chao, Samuel, et al.
Publicado: (2022)

Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected Prostate Cancer Recurrence
por: Cancian, Madeline, et al.
Publicado: (2018)

Feasibility of Dose Escalating [(18)F]fluciclovine Positron Emission Tomography Positive Pelvic Lymph Nodes During Moderately Hypofractionated Radiation Therapy for High-Risk Prostate Cancer
por: McDonald, Andrew M., et al.
Publicado: (2019)

In Molecular Pursuit of Bone Metastasis by Fluciclovine PET
por: Lindenberg, Liza
Publicado: (2017)

TRLS-02. Trial in Progress: A Multicenter Phase 3 Study to Establish the Diagnostic Performance of (18)F-Fluciclovine PET in Detecting Recurrent Brain Metastases after Radiation Therapy (REVELATE)
por: Teoh, Eugene, et al.
Publicado: (2021)

Correlation between (18)F-1-amino-3-fluorocyclobutane-1-carboxylic acid ((18)F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer
por: Saarinen, Irena, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7oucd78nj2rglhapmo9lrkf9k5